MedPath

Mebeverine

Generic Name
Mebeverine
Drug Type
Small Molecule
Chemical Formula
C25H35NO5
CAS Number
3625-06-7
Unique Ingredient Identifier
7F80CC3NNV
Background

Mebeverine has been investigated for the treatment of Irritable Bowel Syndrome and Post-cholecystectomy Gastrointestinal Spasms.

Indication

治疗由肠易激综合症（IBS）引起的腹痛痉挛，肠功能紊乱和肠部不适，治疗由于器质性疾病继发引起的肠痉挛。

Associated Conditions
Abdominal Pain, Abdominal Spasms, Abnormal Bowel Movement Such as Constipation, Diarrhea, Abdominal Pain, Irritable Bowel Syndrome (IBS), Bowel discomfort
Clinical Trials
Related News

To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea

Phase 4
Completed
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
First Posted Date
2023-05-22
Last Posted Date
2023-07-27
Lead Sponsor
Bahria University
Target Recruit Count
162
Registration Number
NCT05867550
Locations
🇵🇰

Bahria University Health Sciences Campus, Karachi, Sindh, Pakistan

Ebastine Versus Mebeverine in IBS Patients

Phase 3
Recruiting
Conditions
IBS - Irritable Bowel Syndrome
IBS
Interventions
First Posted Date
2023-04-18
Last Posted Date
2024-08-21
Lead Sponsor
Guy Boeckxstaens
Target Recruit Count
200
Registration Number
NCT05815602
Locations
🇧🇪

UZLeuven, Leuven, Vlaams-Brabant, Belgium

🇧🇪

GZA, Antwerpen, Belgium

🇧🇪

AZ St-Maarten, Mechelen, Antwerpen, Belgium

and more 2 locations

Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders

Phase 3
Completed
Conditions
Functional Bowel Disorder
Interventions
Drug: Mebeverine+Simethicone
First Posted Date
2022-01-03
Last Posted Date
2024-01-03
Lead Sponsor
Abbott
Target Recruit Count
465
Registration Number
NCT05175131
Locations
🇷🇺

Null Research Facilities, Moscow, Russian Federation

Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder Substitute

Not Applicable
Completed
Conditions
Urinary Bladder Cancer
Incontinence
Urinary Incontinence
Interventions
Drug: Placebo
First Posted Date
2020-11-19
Last Posted Date
2020-11-19
Lead Sponsor
Mansoura University
Target Recruit Count
120
Registration Number
NCT04635566
Locations
🇪🇬

Urology and Nephrology Center, Mansoura, Aldakahlia, Egypt

Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome

Phase 3
Recruiting
Conditions
IBS - Irritable Bowel Syndrome
Interventions
Drug: pentoxyifylline
First Posted Date
2020-01-03
Last Posted Date
2020-01-03
Lead Sponsor
Tanta University
Target Recruit Count
60
Registration Number
NCT04217733
Locations
🇪🇬

Sherief Abd-Elsalam, Tanta, Egypt

Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm

Completed
Conditions
Post-cholecystectomy Gastrointestinal Spasms
Interventions
First Posted Date
2014-10-09
Last Posted Date
2019-06-06
Lead Sponsor
Abbott
Target Recruit Count
220
Registration Number
NCT02260154
Locations
🇷🇺

Research Facility ID ORG-001038, Izhevsk, Russian Federation

🇷🇺

State Budget Institution " Irkutsk State Medical Academy of postgraduate education", Irkutsk, Russian Federation

🇷🇺

Research Facility ID ORG-001035, Chita, Russian Federation

and more 18 locations

Management of Irritable Bowel Syndrome in Primary Care (MIBS Trial)

Phase 4
Completed
Conditions
Irritable Bowel Syndrome
Interventions
Drug: placebo
Behavioral: CBT website with minimal support
Behavioral: No website
Behavioral: CBT website with support
First Posted Date
2009-07-08
Last Posted Date
2021-04-30
Lead Sponsor
Hazel Everitt
Target Recruit Count
135
Registration Number
NCT00934973
Locations
🇬🇧

University of Southampton, Southampton, Hampshire, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy